iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus Life gets final USFDA approval for topical acne treatment gel

7 Jun 2022 , 08:42 AM

A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples. Adapalene works by affecting the growth of cells and decreasing swelling and inflammation and Benzoyl Peroxide works by reducing the amount of acne-causing bacteria and by causing the skin to dry and peel off, Zydus Lifesciences said in a statement on Tuesday. Adapalene and Benzoyl Peroxide Topical Gel had a market size of $195 million (as per IQVIA MAT April 22). The drug will be manufactured at groups topical facility at Ahmedabad. The group now has 315 approvals and has so far filed over 420 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences (formerly known as Cadila Healthcare), a leading Indian pharmaceutical company is a fully integrated, global healthcare provider. Zydus Lifesciences reported 41.5% fall in consolidated net profit to Rs 397.4 crore on a 5.3% increase in total income from operations to Rs 3,863.8 crore in Q4 FY22 over Q4 FY21. Shares of Zydus Lifesciences rose 0.47% to Rs 364.65 on Monday. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.